The FDA stated that they were prioritising applications of companies who could supply the largest volumes of inventory the quickest.
A2M's CEO said their application was subject to stock availability.
It suggests they do not have a surplus of stock sitting around on shelves gathering dust that would be better off sent to USA and that they are making them wait for new stock to be produced later.
If they've promised the USA new stock in September etc. then there's not really any need for the FDA to fast track an approval ahead of others supplying sooner.
It could be a bit of a gamble but most likely also reflects the urgency and risk/reward they see in actually entering the USA IF market. The margins are apparently slim on IF sales there. So if they were to reroute Chinese-bound inventory to USA they would just be losing profits. IMO
A2M Price at posting:
$4.44 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)